Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Globe Newswire•09/11/2026•16:01 ET
1
Key Highlights
- ➤$213.4 million cash, equivalents and short-term investments expected to fund operations into 2028
- ➤Tanruprubart U.S. BLA submission with FORWARD data expected in fourth quarter of 2026
- ➤Vonaprument ARCHER II Month 15 primary endpoint assessment expected in fourth quarter of 2026
- ➤$51.2 million third-quarter net loss, or $0.25 per share, versus $54.9 million loss
- ➤Oxford Finance credit facility provides up to $200 million, including $50 million initially drawn
Expert Statements
Douglas Love, President and Chief Executive Officer of Annexon
“Annexon is well-positioned for a transformative next 12 months, with multiple value-creating milestones expected across our differentiated upstream C1q platform”
Douglas Love, President and Chief Executive Officer of Annexon
“By targeting C1q tanruprubart and vonaprument have each demonstrated first-in-kind benefits in clinical trials to date, with tanruprubart accelerating functional recovery in Guillain-Barré syndrome (GBS) and vonaprument protecting vision in geographic atrophy (GA). Together, they have the potential to become groundbreaking therapies for millions of patients worldwide.”
Douglas Love, President and Chief Executive Officer of Annexon
“In the third quarter, we advanced both programs, strengthened our balance sheet and added experienced leaders to our Board of Directors, advisory board, and team. We enter the final months of the year with significant focus and momentum to deliver on our mission to help millions live their best lives.”
Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts
Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Package Anticipated in Q4 2026; Tanruprubart EU MAA Currently Under Review
Get started
Create a free account to read the full story.